Eli Lilly Other Non-Current Liabilities 2010-2024 | LLY

Eli Lilly other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • Eli Lilly other non-current liabilities for the quarter ending September 30, 2024 were $6.118B, a 13.84% increase year-over-year.
  • Eli Lilly other non-current liabilities for 2023 were $6.09B, a 10.05% increase from 2022.
  • Eli Lilly other non-current liabilities for 2022 were $5.534B, a 0.55% decline from 2021.
  • Eli Lilly other non-current liabilities for 2021 were $5.564B, a 0.34% increase from 2020.
Eli Lilly Annual Other Non-Current Liabilities
(Millions of US $)
2023 $6,090
2022 $5,534
2021 $5,564
2020 $5,545
2019 $5,108
2018 $5,058
2017 $5,323
2016 $2,917
2015 $2,616
2014 $3,283
2013 $2,942
2012 $2,704
2011 $2,660
2010 $3,004
2009 $2,398
Eli Lilly Quarterly Other Non-Current Liabilities
(Millions of US $)
2024-09-30 $6,118
2024-06-30 $5,967
2024-03-31 $6,460
2023-12-31 $6,090
2023-09-30 $5,374
2023-06-30 $5,283
2023-03-31 $5,665
2022-12-31 $5,534
2022-09-30 $5,495
2022-06-30 $5,341
2022-03-31 $5,692
2021-12-31 $5,564
2021-09-30 $5,517
2021-06-30 $5,540
2021-03-31 $5,655
2020-12-31 $5,545
2020-09-30 $5,095
2020-06-30 $5,204
2020-03-31 $5,495
2019-12-31 $5,108
2019-09-30 $4,627
2019-06-30 $4,629
2019-03-31 $4,930
2018-12-31 $5,058
2018-09-30 $5,288
2018-06-30 $5,092
2018-03-31 $5,322
2017-12-31 $5,323
2017-09-30 $2,999
2017-06-30 $3,149
2017-03-31 $2,979
2016-12-31 $2,917
2016-09-30 $2,917
2016-06-30 $2,712
2016-03-31 $2,737
2015-12-31 $2,616
2015-09-30 $2,333
2015-06-30 $2,481
2015-03-31 $2,428
2014-12-31 $3,283
2014-09-30 $2,575
2014-06-30 $2,777
2014-03-31 $2,968
2013-12-31 $2,942
2013-09-30 $2,122
2013-06-30 $2,669
2013-03-31 $2,659
2012-12-31 $2,704
2012-09-30 $3,090
2012-06-30 $2,680
2012-03-31 $2,692
2011-12-31 $2,660
2011-09-30 $2,508
2011-06-30 $2,833
2011-03-31 $3,111
2010-12-31 $3,004
2010-09-30 $2,517
2010-06-30 $2,338
2010-03-31 $2,311
2009-12-31 $2,398
2009-09-30 $2,275
2009-06-30 $2,301
2009-03-31 $2,263
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $692.744B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94